Latest News
-
jan
22Hart to Treat Diseases (HTDS) Evaluating Business Proposal
Jan 22, 2010 -- Hard to Treat Diseases, Inc. (HTDS:PK) subsidiary Slavica Bio Chem recently announced entry into the stem cell bank development. An unsolicited business proposal is currently being evaluated by the company from an obstetrician type medical company. This company is engaged in a treatment for pre-term labor and induction of labor. These symptoms affect millions of people worldwide. HTDS management hopes to build its own stem cell bank and laboratories in Serbia under supervision of its Slavica Biochem medical team and has attracted many inquiries from medical companies. As the issuer has no desire to subscribe to the Pink Sheets filing service a business plan is currently being drafted by the company medical team and will be posted on the company web site in due time.
-
jan
19Hard to Treat Diseases Inc. (HTDS) Stem Cell Developments
FRANKFURT, Jan 19, 2010 -- Hard to Treat Diseases, Inc. (HTDS:PK) and its operating subsidiary Slavica BioChem want to point the shareholders back to the press release from Oct 29, 2009, where the company announced news about a possible merger with a EU based, stem-cell research company. HTDS postponed these merger negotiations due to certain HTDS' "followers" certain intrusive intervention and a massive short position on HTDS security. As previously announced the company has began a project to build its own stem cell lab. Details will be posted on the company web site under the section "Company News" as the company no longer subscribes to Pink Sheets filing service. HTDS' sale of the MindUp program to Hiru Corporation in Q4 2009 has now created an opportunity for the company to create its own stem cell facility.